Karen Foster compensation by year
BIOLIFE SOLUTIONS Summary Compensation Table · all 3 fiscal years held| Component | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Salary | $356,500 | $382,000 | $430,000 |
| Bonus | $0 | $0 | $0 |
| Stock awards | $891,900 | $727,677 | $901,210 |
| Option awards | $0 | $0 | $0 |
| Non-equity incentive | $84,252 | $0 | $170,280 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $12,200 | $13,200 | $13,649 |
| Total | $1,344,852 | $1,122,877 | $1,515,139 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIOLIFE SOLUTIONS INC DEF 14A filed July 8, 2025, accession 0000834365-25-000007, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 20,651 | $536,100 | — |
| PSU | 20,651 | $536,100 | — |
| PSU | 16,978 | $440,749 | — |
| RSU | 9,551 | $247,944 | — |
| RSU | 5,112 | $132,708 | — |
| RSU | 260 | $6,750 | — |
| Option | 100,000 | — | $1.90 |
Per the Outstanding Equity Awards at Fiscal Year-End table in BIOLIFE SOLUTIONS INC's FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
14 Form 4 lines since the FY2024 proxy (filed July 8, 2025)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-03-23 | Sale | 10b5-1 | 2,577 | $19.17 | 108,758 |
| 2026-03-19 | Tax withholding | — | 1,907 | $19.12 | 111,335 |
| 2026-03-09 | Sale | — | 500 | $20.00 | 113,242 |
| 2026-03-05 | Sale | — | 96,923 | $20.15 | 113,742 |
| 2026-03-03 | Sale | 10b5-1 | 418 | $20.74 | 210,665 |
| 2026-02-24 | Grant or award | — | 32,112 | — | 224,096 |
| 2026-02-24 | Tax withholding | — | 13,013 | $22.65 | 211,083 |
| 2026-01-06 | Sale | 10b5-1 | 335 | $25.59 | 191,984 |
The 8 most recent of 14 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Change-in-control & termination
estimated payments BIOLIFE SOLUTIONS discloses, by trigger · FY2024| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Death | — | $1,900,350 | — | $2,070,630 |
| Involuntary termination without cause | $430,000 | $1,900,350 | $25,491 | $2,355,841 |
| Change in control and resignation for good reason | $430,000 | $1,900,350 | $25,491 | $2,526,121 |
| Disability | — | $1,900,350 | — | $2,070,630 |
| Change in control and involuntary termination | $430,000 | $1,900,350 | $25,491 | $2,526,121 |
| Resignation for good reason, no change in control | $430,000 | $1,900,350 | $25,491 | $2,355,841 |
Per the Potential Payments Upon Termination or Change in Control table in BIOLIFE SOLUTIONS INC's FY2024 proxy. Estimates as the company printed them; a dash means it printed no figure.
BIOLIFE SOLUTIONS’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Roderick de Greef | Chief Executive Officer and Chairman of the Board | $7,046,205 |
| Troy Wichterman | Chief Financial Officer | $2,554,007 |
| Aby Mathew | Executive Vice President and Chief Scientific Officer | $1,733,494 |
| Karen Foster · this page | Chief Quality and Operations Officer | $1,515,139 |
| Garrie Richardson | Former Chief Revenue Officer | $1,387,288 |
| Todd Berard | Chief Commercial Officer | $1,127,495 |
The full BIOLIFE SOLUTIONS compensation record
free company briefThis page is one person within BIOLIFE SOLUTIONS's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order BIOLIFE SOLUTIONS's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BIOLIFE SOLUTIONS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat